Singapore is not a casual participant in the global life sciences industry. It is a deliberate, government-backed hub that has been built over two decades into one of Asia's most significant nodes for biomedical manufacturing, pharmaceutical research, and clinical trials.
Eight of the world's top ten major pharmaceutical companies have established regional headquarters here, including Abbott, Johnson and Johnson, and Pfizer. In 2023, the biomedical sector contributed 2.6% to Singapore's GDP, manufacturing products valued at nearly S$38 billion for global markets. The Economic Development Board's RIE2030 plan commits S$37 billion to science and technology development, with health and biomedical sciences as a central pillar.
Behind these headline figures is a growing ecosystem of companies that most general insurers have little experience dealing with: biotech startups, contract research organisations (CROs), medical device developers, pharmaceutical manufacturers, and academic institutions running clinical trials. These businesses carry a risk profile that is genuinely different from most commercial operations, and the insurance that addresses those risks is correspondingly specialised.
This post explains what life sciences insurance covers, why standard commercial policies fall short for this sector, and what Singapore-based life sciences companies and institutions should be thinking about.
What makes life sciences risk different?
Most businesses can draw a reasonably clear line between their professional services and their physical products. A consultant gives advice. A manufacturer makes goods. The liability for each sits in a separate policy: professional indemnity for the advice, product liability for the goods.
Life sciences businesses blur that line completely. A contract research organisation (CRO) provides professional services in designing and managing a clinical trial, but the trial involves the administration of an investigational drug or medical device to human subjects. A pharmaceutical manufacturer makes physical products, but the design of those products emerged from scientific research and professional judgement. A biotech company developing a diagnostic device is simultaneously a technology company, a professional services firm, and a product manufacturer.
When something goes wrong in this environment, it rarely fits neatly into one category. Consider what a single adverse event in a clinical trial can involve: a participant injured by the investigational product; a question of whether the informed consent document adequately disclosed the risks; a dispute over whether the trial design itself was flawed; and a data integrity question about whether the results from this trial are now usable. That is a product liability claim, a professional indemnity claim, a participant compensation claim, and a business interruption issue, all arising from one event.
Standard commercial policies are not designed for this. A general product liability policy written for a manufacturer of consumer goods will typically contain exclusions for clinical trials, experimental products, and products that have not yet received regulatory approval. A standard professional indemnity policy written for a consulting firm will typically not cover liability arising from bodily injury to a human research subject.
The gap between what standard policies say they cover and what a life sciences business actually does is where uninsured losses accumulate.
Who needs life sciences insurance in Singapore?
The category is broader than most people assume. It extends well beyond the large pharmaceutical manufacturers visible at Tuas Biomedical Park and Biopolis.
Pharmaceutical and biopharmaceutical companies. Manufacturers of drugs, biologics, vaccines, and other regulated therapeutic products. The liability exposure here runs from contamination of a manufacturing batch, which can trigger a product recall and third-party claims, to adverse reactions in patients who receive a commercial product.
Medical device companies. Developers and manufacturers of devices from diagnostic equipment to implantable surgical instruments. A device that causes harm creates product liability exposure. A device that fails to perform as specified creates professional liability exposure for the company that designed it. The two are rarely separable.
Biotech and health technology firms. Companies developing novel therapies, diagnostics, genomics tools, and AI-enabled health technologies. This category is growing rapidly in Singapore: the number of Singapore-based biotech startups has grown from fewer than 10 in 2012 to around 65 in 2023, and is expected to increase by more than 60 per cent between 2022 and 2032 according to the EDB. Many of these companies are at the research and development stage, which means their products have not yet received regulatory approval and their activities may not be covered by standard product liability wordings.
Contract research organisations (CROs) and contract development and manufacturing organisations (CDMOs). Companies that provide research, trial management, regulatory, and manufacturing services to pharmaceutical and biotech clients. A CRO that makes an error in trial data management can expose its client to a regulatory failure worth millions in wasted trial cost, and expose itself to a professional indemnity claim of equivalent scale. Singapore's CRO sector is growing: contract research organisations are proliferating as companies outsource regulatory and clinical trial processes.
Academic institutions and hospitals conducting clinical research. Universities, research institutes, and hospitals that run clinical trials under investigator-initiated trial protocols, or that collaborate with commercial sponsors. The liability for injury to a research subject can attach to the institution conducting the trial, not only to the commercial sponsor of the drug or device being tested.
Distributors and importers of regulated medical products. Companies that bring pharmaceutical products or medical devices into Singapore for commercial distribution. As we discussed in Product Liability Insurance in Singapore, the importer is often the first port of call for a claim where the overseas manufacturer is unreachable. For regulated medical products, that exposure is amplified by the potential severity of harm.
What does life sciences insurance cover?
Specialist life sciences cover is typically structured as a combined package that addresses the interconnected risks in a single, coordinated policy. The key components are as follows.
Products and services liability. Covers legal liability for bodily injury or property damage caused by a product the company manufactured, supplied, or distributed, and by the professional services it provided. The combination in a single wording is important: it prevents the situation where a claim sits at the boundary between a product and a service, with each policy pointing to the other.
Clinical trials liability. Covers liability for injury to research subjects participating in a clinical trial, including no-fault compensation where the participant is harmed even in the absence of negligence on the sponsor's part. This is a significant difference from standard liability policies, which typically require fault to be established before a claim is paid. No-fault compensation reflects the ethical obligation to research subjects who suffer harm while voluntarily advancing scientific knowledge. Cover extends across all phases of clinical trials, from Phase I safety studies in healthy volunteers through to Phase III efficacy studies in patient populations.
Professional indemnity. Covers claims arising from errors in professional services: a flawed trial protocol, a mistake in regulatory filing, incorrect analytical results from a laboratory, or advice that causes a client's programme to fail. For CROs and CDMOs, this is the core liability exposure.
Cyber liability. Life sciences companies hold significant volumes of sensitive data: trial participant data protected under the PDPA, proprietary research data, and regulatory submission packages that represent years of work. A data breach or ransomware attack creates regulatory exposure, reputational damage, and, for organisations conducting trials with patient health data, a heightened duty of care. Cyber cover addresses the costs of responding to and managing a breach. We covered the cyber landscape for Singapore businesses in more detail in Cyber Insurance in Singapore.
Property cover with life sciences extensions. Standard property insurance is not designed for laboratory and manufacturing environments. Life sciences property cover includes specific extensions for contamination incidents, radioactive contamination, loss of research and development income (where a contamination event or facility loss disrupts a programme), condemnation of undamaged product batches, and cover for scientific animals used in pre-clinical research.
The clinical trials dimension: why Singapore is a relevant jurisdiction
Singapore is an active clinical trial market. The Health Sciences Authority (HSA) oversees the regulatory framework for clinical trials under the Health Products Act, and Singapore's regulatory status has been recognised at the highest level: Singapore is the first regulator to have received the highest maturity level in the World Health Organization's classification of regulatory authorities for medical products. That standing makes Singapore an attractive jurisdiction for multi-country trial sponsors seeking a credible regulatory anchor in Asia.
For any organisation conducting a clinical trial in Singapore involving human subjects, insurance is not merely prudent. It is a regulatory requirement. The HSA requires sponsors of clinical trials to hold appropriate clinical trial insurance as a condition of approval. The policy must cover participant injury, including no-fault compensation, and must be in place before the first participant is enrolled.
For multinational trial programmes, the coordination of local compulsory insurance with a master policy covering the global programme is an important structuring question. Where a local policy has compulsory liability limits that are lower than the actual settlement reached, a master policy with a difference-in-limits provision allows the global programme to respond to the shortfall. Without it, the sponsor is exposed above the local compulsory cap.
What to think about if your organisation is in this space
For a life sciences company or research institution in Singapore reviewing its insurance arrangements, here are the questions worth asking.
Do your current policies have exclusions for clinical trials, investigational products, or pre-approval activities? Standard product liability and professional indemnity policies often contain these exclusions. If your organisation's work falls in any of these categories, standard policies may not respond.
If you conduct clinical trials, does your clinical trial insurance meet the HSA's requirements for participant coverage, including no-fault compensation? Is the coverage limit adequate for the therapeutic area and patient population involved?
If you provide services to pharmaceutical or biotech clients as a CRO or CDMO, does your professional indemnity policy cover errors in trial data, regulatory submissions, and laboratory analysis? What is the policy limit relative to the scale of the client programmes you support?
If your organisation holds research data, trial participant data, or proprietary biological or chemical data, how is that data protected under your cyber policy, and how does the PDPA notification obligation apply to your specific data environment?
Life sciences insurance is not a product most general insurance intermediaries place regularly. The risk profile is specific, the wording questions are technical, and the regulatory requirements in different countries add an additional layer of complexity for any organisation running multinational programmes.
If your organisation is in the life sciences space and would like to understand how your current insurance arrangements sit against your actual activities, we would be glad to discuss it.
This article provides general information only. It is not insurance advice. Policy availability, terms, conditions, and exclusions vary by insurer and product, and cover is subject to the full policy wording. Please contact TZY CO for advice on your specific situation.